Sign In
Buy PSTX
$9.50
+0 (+0%)
At Close: Apr 04, 2025
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
09:16am, Monday, 09'th Sep 2024
Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 mil
Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, Se
Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy Demonstrates potential of stem cell memory T cells (TSCM), a key d
Poseida Therapeutics to Present at Upcoming Investor Conferences
04:05pm, Thursday, 29'th Aug 2024
SAN DIEGO , Aug. 29, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatment
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
06:55pm, Monday, 05'th Aug 2024
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.32 per share a year ago.
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
04:05pm, Monday, 05'th Aug 2024
Continued Roche CAR-T partnership progress with agreement for Poseida to initiate Phase 1b portion of P-BCMA-ALLO1 clinical trial Strong Astellas research collaboration momentum with nomination of f
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
08:49am, Tuesday, 30'th Jul 2024
Penny stocks represent an interesting investment opportunity.
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
01:01pm, Friday, 19'th Jul 2024
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
04:05pm, Monday, 01'st Jul 2024
SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
04:05pm, Monday, 03'rd Jun 2024
SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatment
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
04:05pm, Tuesday, 14'th May 2024
Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated $95
Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profile Preclinical P-FVIII-10
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO , May 1, 2024 /PRNewswire/ -- Astellas Pharma
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
08:00am, Thursday, 18'th Apr 2024
Company to deliver three oral and three poster presentations highlighting its portfolio of non-viral genetic medicines Presentations to include new pre-clinical data on lead non-viral candidates P-KLK
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
09:00am, Wednesday, 17'th Apr 2024
Fully non-viral approach to genetic medicine employs differentiated gene delivery, gene editing and gene insertion technology Progressing two fully non-viral programs in rare disease with significa
